Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Clinical Features and Prognosis of Late-onset Systemic Lupus Erythematosus: Results from the 1000 Faces of Lupus Study

SHELIZA LALANI, JANET POPE, FAYE de LEON and CHRISTINE PESCHKEN
The Journal of Rheumatology January 2010, 37 (1) 38-44; DOI: https://doi.org/10.3899/jrheum.080957
SHELIZA LALANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JANET POPE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: janet.pope@sjhc.london.on.ca
FAYE de LEON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTINE PESCHKEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Percentage of women at different ages of SLE onset for the overall 1000 Faces of Lupus cohort. Pediatric patients were excluded from analyses in this study.

Tables

  • Figures
    • View popup
    Table 1.

    Demographics of early onset (< 50 years) vs late onset (≥ 50 years) SLE.

    CharacteristicEarly OnsetLate Onsetp
    N (%)1367 (89.4)161 (10.5)
    Female: male8.83:17.47:10.5
    Mean current age, yrs41.64 ± 15.0167.09 ± 8.42
    Mean age at diagnosis, yrs26.71 ± 11.3657.90 ± 7.01
    Mean disease duration, yrs15.02 ± 10.489.3 ± 6.1< 0.001
    Caucasian (%)760 (55.6)120 (74.5)
    Asian (%)249 (18.2)5 (3.1)
    Black (%)122 (8.9)8 (5.0)
    Aboriginal (%)71 (5.2)5 (3.1)
    Latin/Hispanic (%)22 (1.6)2 (1.2)
    Jewish (%)22 (1.6)4 (2.5)
    Middle Eastern (%)21 (1.5)3 (1.9)
    • View popup
    Table 2.

    American College of Rheumatology criteria in early onset (< 50 yrs) vs late onset (≥ 50 yrs) SLE.

    Early OnsetLate Onsetp
    Mean no. of ACR criteria met5.98 ± 1.685.24 ± 1.440.007*
    Malar rash813 (63.9)72 (51.1)0.002*
    Renal613 (49.0)33 (24.1)< 0.0001*
    Proteinuria252 (80.3)6 (37.5)< 0.0001*
    Neurological130 (11.0)6 (4.3)0.01*
    Hematologic1010 (77.9)102 (68.0)0.006*
    Immunologic1128 (86.3)118 (79.7)0.006*
    Serositis442 (36.1)45 (32.1)0.2
    Pleuritis/pleural effusion209 (76.8)25 (73.5)0.4
    Seizures46 (58.2)1 (20.0)0.1
    Psychosis29 (37.7)1 (25.0)0.5
    Hemolytic anemia111 (21.3)8 (13.1)0.09
    Discoid rash183 (15.4)24 (17.9)0.3
    Photosensitivity676 (54.2)77 (55.0)0.5
    Arthritis1041 (79.8)125 (83.9)0.1
    Pericarditis116 (43.8)15 (45.4)0.5
    Cellular casts152 (50.2)11 (64.7)0.2
    Oral/nasal ulcerations668 (53.4)80 (58.0)0.2
    Lupus inhibitor/anticoagulant52 (19.3)8 (27.6)0.2
    False-positive VDRL19 (6.9)4 (13.3)0.2
    Thrombocytopenia171 (31.8)21 (33.9)0.4
    Lymphopenia385 (69.7)46 (70.8)0.5
    • ↵* Statistically significant. ACR: American College of Rheumatology; VDRL: Venereal Disease Research Laboratory.

    • View popup
    Table 3.

    Clinical manifestations of SLE (early vs late onset) at first database visit.

    FeatureEarly Onset, n (%)Late Onset, n (%)p
    Fever183 (16.7)10 (7.9)0.009*
    Nephrotic syndrome64 (6)00.001*
    Alopecia02 (2.5)0.016*
    Arthralgias582 (52.7)75 (58.1)0.3
    Weight loss188 (17.3)25 (19.5)0.5
    Fatigue559 (50.9)70 (54.7)0.5
    Inflammatory arthritis238 (21.7)37 (29.1)0.07
    Deforming arthritis80 (7.3)12 (9.7)0.4
    Sicca complex77 (13.3)14 (16.5)0.4
    Fibromyalgia155 (23.6)18 (19.1)0.4
    Raynaud’s434 (39.3)61 (46.9)0.1
    Myositis28 (2.6)5 (4.0)0.4
    • ↵* Statistically significant.

    • View popup
    Table 4.

    Laboratory measures of SLE (early vs late onset).

    Early OnsetLate Onsetp
    ANA-positive1282 (97.0)149 (96.8)0.5
    Anti-dsDNA-positive514 (80.3)64 (79.0)0.4
    Anti-Sm-positive183 (29.9)8 (10.5)< 0.0001*
    Anti-Ro/SSA antibodies330 (33.5)32 (27.8)0.2
    Anti-RNP antibodies274 (28.8)16 (13.8)< 0.0001*
    Anti-La/SSB antibodies135 (14.4)12 (10.6)0.3
    Anti-Jo1 antibodies42 (4.5)1 (0.9)0.08
    Anti-Scl70 antibodies17 (1.9)4 (3.5)0.3
    Antiphospholipid-positive306 (50.0)32 (42.7)0.1
    Anticardiolipin-positive164 (58.0)16 (55.2)0.5
    Low serum levels of complements (ever)458 (41.8)31 (25.0)< 0.0001*
    pANCA29 (3.2)5 (4.4)0.4
    cANCA9 (1.0)3 (2.7)0.1
    • ↵* Statistically significant. ANA: antinuclear antibody; dsDNA: double-stranded DNA; Sm: Smith; RNP: ribonucleoprotein; pANCA: perinuclear ANCA; cANCA: cytoplasmic ANCA.

    • View popup
    Table 5.

    Charlson Comorbidity Index.

    Early Onset (%)Late Onset (%)p
    Charlson Index score (mean ± SD)1.25 ± 0.751.43 ± 1.120.01*
    Congestive heart failure13 (1.9)8 (7.1)0.02*
    Myocardial infarction19 (2.8)8 (7.1)0.1
    Peripheral vascular disease8 (1.2)00.2
    Cerebrovascular disease49 (7.2)12 (10.6)0.4
    Dementia1 (0.1)1 (0.9)0.4
    Peptic ulcer disease29 (4.3)14 (12.5)0.006*
    Moderate to severe renal disease25 (3.7)00.02*
    COPD16 (2.4)7 (6.2)0.1
    Mild liver disease3 (0.4)3 (2.7)0.1
    Diabetes—mild to moderate19 (2.8)8 (7.1)0.1
    Diabetes with end organ damage3 (0.4)2 (2.7)0.1
    Any tumor19 (2.8)8 (7.1)0.09
    • ↵* Statistically significant. COPD: chronic obstructive pulmonary disease.

    • View popup
    Table 6.

    Disease activity and damage in early onset (< 50 yrs) vs late onset (≥ 50 yrs) SLE.

    Early OnsetLate Onsetp
    Mean SLAM score5.19 ± 3.867.07 ± 4.41< 0.0001*
    Mean SLEDAI score4.29 ± 4.314.39 + 4.180.8
    Mean no. with lupus flare over last year0.89 ± 0.981.04 ± 0.980.2
    Mean disease activity (VAS)3.43 ± 2.814.11 ± 2.630.04*
    Mean unusual fatigue (VAS)4.43 ± 3.234.73 ± 2.600.4
    SLAQ, self-reported, %
      Rash/nausea after sun exposure33.548.70.05*
      Shortness of breath40.159.00.02*
      Numbness/tingling32.755.30.002*
      Muscle weakness52.864.60.0008*
      Mean SLICC score1.50 ± 1.941.80 ± 1.670.09
    • ↵* Statistically significant. SLAM: SLE activity measure; SLEDAI: SLE Disease Activity Index; VAS: visual analog scale; SLAQ: SLE Activity Questionnaire; SLICC: Systemic Lupus International Collaborating Clinics.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 1
1 Jan 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Features and Prognosis of Late-onset Systemic Lupus Erythematosus: Results from the 1000 Faces of Lupus Study
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Clinical Features and Prognosis of Late-onset Systemic Lupus Erythematosus: Results from the 1000 Faces of Lupus Study
SHELIZA LALANI, JANET POPE, FAYE de LEON, CHRISTINE PESCHKEN
The Journal of Rheumatology Jan 2010, 37 (1) 38-44; DOI: 10.3899/jrheum.080957

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Clinical Features and Prognosis of Late-onset Systemic Lupus Erythematosus: Results from the 1000 Faces of Lupus Study
SHELIZA LALANI, JANET POPE, FAYE de LEON, CHRISTINE PESCHKEN
The Journal of Rheumatology Jan 2010, 37 (1) 38-44; DOI: 10.3899/jrheum.080957
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications
  • Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials
  • Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire